Table 1 Clinical features of patients
| Â | Â | Number of patients (rates) | |
|---|---|---|---|
Non-tumor tissue | HCC | ||
Races | White | 26 (63.4%) | 184 (49.6%) |
American Indian or Alaska native | 0 (0%) | 2 (0.5%) | |
Black or African American | 7 (17.1%) | 17 (4.6%) | |
Asian | 5 (12.2%) | 158 (42.6%) | |
Not reported | 3 (7.3%) | 10 (2.7%) | |
Age (year) |  | 20–78 | 16–85 |
Gender | Male | 18 (43.9%) | 250 (67.4%) |
Female | 23 (56.1%) | 121 (32.6%) | |
History of HCC factor | None | 14 (34.1%) | 91 (24.5%) |
Alcohol consumption | 6 (14.6%) | 68 (18.3%) | |
Hepatitis B | 6 (14.6%) | 75 (20.2%) | |
Hepatitis C | 5 (12.2%) | 32 (8.6%) | |
Non-alcoholic fatty liver disease | 2 (4.9%) | 11 (3.0%) | |
Hemochromatosis | 0 (0%) | 5 (1.3%) | |
Complex | 1 (2.4%) | 58 (15.6%) | |
Other | 4 (9.8%) | 12 (3.2%) | |
No data | 3 (7.3%) | 19 (5.1%) | |
Histologic grade | G1 | 5 (12.2%) | 55 (14.8%) |
G2 | 20 (48.8%) | 177 (47.7%) | |
G3 | 14 (34.1%) | 122 (32.9%) | |
G4 | 2 (4.9%) | 12 (3.2%) | |
No data | 0 (0%) | 5 (1.3%) | |
AJCC TNM staging systema (presence or absence of distant metastasis) | M0 | 27 (65.9%) | 266 (71.7%) |
M1 | 1 (2.4%) | 4 (1.1%) | |
MXb | 13 (31.7%) | 101 (27.2%) | |
AJCC TNM staging system (lymph node involvement) | N0 | 25 (61.0%) | 252 (67.9%) |
N1 | 1 (2.4%) | 4 (1.1%) | |
NXc | 14 (34.1%) | 114 (30.7%) | |
No data | 1 (2.4%) | 1 (0.3%) | |
AJCC TNM staging system (tumor size and extent of tumors) | T1 | 19 (46.3%) | 181 (48.8%) |
T2 | 10 (24.4%) | 94 (25.3%) | |
T3 | 9 (22.0%) | 80 (21.6%) | |
T4 | 3 (7.3%) | 13 (3.5%) | |
Otherd | 0 (0%) | 3 (0.8%) | |
AJCC pathological stage | Stage I | 17 (41.5%) | 171 (46.1%) |
Stage II | 7 (17.1%) | 86 (23.2%) | |
Stage III | 8 (19.5%) | 85 (22.9%) | |
Stage IV | 1 (2.4%) | 5 (1.3%) | |
No datae | 8 (19.5%) | 22 (5.9%) | |
Othere | 0 (0%) | 2 (0.5%) | |